AUTHORS
Karthik Ramasamy, MD PhD, Kara-Louise Royle, PhD2, Ziyu Ding3, Ruth de Tute, PhD, MSc, FRCPath4, Matthew Jenner, MBBS5, Ceri Bygrave, MBBCh6, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD7, Laura Chiecchio, PhD8, Guy Pratt9, Catherine Olivier10, Lorna Barnard11, Sharon Jackson12, Charlotte Kennaway13, Gordon Cook, MD, PhD, DSc14, Alan Chant15, David Meads16, Bryony Dawkins17, Michael Chapman, PhD18, Graham Jackson, MBBS, DM, FRCP, FRCPath, MA19, Andrew Chantry20, Eileen Boyle, MD PhD21, Christopher Parrish, PhD, FRCPath, MA, MBBChir, MRCP22, Dean Smith23, Y L Tracey Chan, PhD, FRCPath, MBChB24, Roger Owen, FRCPath25, David Cairns, PhD26, Kwee Yong, Prof27
AFFILIATIONS
1 University of Oxford and Oxford University Hospitals, Oxford, Oxfordshire, United Kingdom
2 Leeds Cancer Research UK CTU, University of Leeds,, Leeds, United Kingdom
3 Leeds Cancer Research UK CTU, University of Leeds,, Leeds, United Kingdom
4 Haematological Malignancies Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom
5 Department of Haematology, University Hospital Southampton,, SOUTHAMPTON, United Kingdom
6 University Hospital of Wales, Cardiff, UK Cardiff University, Division of Cancer and Genetics, Cardiff, Cardiff, United Kingdom
7 University College Hospital, London, UK, London, United Kingdom
8 Wessex Genomics Laboratory Service (Salisbury), University Hospital Southampton, UK, Salisbury, United Kingdom
9 Institute of Immunology and Immunotherapy, University of Birmingham, UK, Birmingham, United Kingdom
10 Leeds Cancer Research UK CTU, University of Leeds,, Leeds, United Kingdom
11 Leeds Cancer Research UK CTU, University of Leeds,, Leeds, United Kingdom
12 Leeds Cancer Research UK CTU, University of Leeds,, Leeds, United Kingdom
13 Leeds Cancer Research UK CTU, University of Leeds,, Leeds, United Kingdom
14 Leeds Cancer Research UK CTU, University of Leeds,, Leeds, United Kingdom
15 PPI, Oxford, United Kingdom
16 Academic Unit of Heath Economics, University of Leeds, Leeds, UK, Leeds, United Kingdom
17 Academic Unit of Heath Economics, University of Leeds, Leeds, UK, Leeds, United Kingdom
18 Department of Haematology, University of Cambridge, Cambridge, United Kingdom
19 Newcastle University, Newcastle, Newcastle, United Kingdom
20 University of Sheffield, Sheffield, Sheffield, United Kingdom
21 UCL Cancer Institute, University College London, London, United Kingdom
22 Leeds Cancer Research UK CTU, University of Leeds,, Leeds, United Kingdom
23 University of nottingham, Nottingham, United Kingdom
24 Clinical Immunology Service, University of Birmingham, Birmingham, United Kingdom
25 Haematological Malignancies Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom
26 Leeds Cancer Research UK CTU, University of Leeds,, Leeds, United Kingdom
27 UCL Cancer Institute, University College London, London, United Kingdom
ABSTRACT
Background: Despite improved clinical outcomes in transplant eligible (TE) newly diagnosed myeloma (NDMM) patients, those with genetically high-risk (HR) disease continue to experience short survival. The IMS/IMWG high risk criteria confirm poor outcomes in double-hit [2 high-risk cytogenetic abnormalities (HRCA)] disease in comparison to patients with single, or no HRCA (Avet-Loiseau JCO 2025). We report results from the initial design of the RADAR trial, where double hit HRCA patients received bortezomib, lenalidomide, dexamethasone and cyclophosphamide VRDc induction followed by single autologous stem cell transplant (ASCT) and were randomised to receive either VRD consolidation followed by R maintenance or addition of Isatuximab to both consolidation (IsaVRD) and maintenance (R-Isa).
Study Design/ Methods
UK-MRA RADAR is a prospective, national, multi-centre, risk-adapted phase II/III trial for TE NDMM patients. At trial inception (2020) patients received 4 x 21-day cycles of VRDc induction (V: Weekly; R:D1-14; D:Weekly; c: D1 and D8 in a 21-day cycle), followed by ASCT. At 100-days post-ASCT patients entered a high-risk pathway based on the presence of ≥2 HRCA (t(4;14), t(14;16), t(14:20), del(17p) and gain(1q)) defined by standard-of-care NHS cytogenetic (FISH/MLPA) testing. Patients with HR disease were randomised to 4 x 21 day cycles of either Isa-VRD consolidation (Isa: Weekly C1, D1 and D8 C2, D1 and D15 C3+; V: Weekly; R:D1-14; D:Weekly) and 28 day cycles of IsaR maintenance (Isa: D1 and D15, R: D1 – D21) or VRD (V: Weekly; R:D1-14; D:Weekly) consolidation and R (D1 – D21) maintenance until progression. Randomisation was stratified by centre, response at 100 days post-ASCT (<VGPR, ≥VGPR), and number of HRCA at trial registration (2, ≥3). Flow MRD testing (10-5) was done post-induction, post-transplant and 3, 6,12 and 18 months after starting consolidation.
Primary endpoint was progression-free survival (PFS) at 28 months post-randomisation. Each arm was a one-stage design to determine improved activity compared to historical data. However, RADAR was amended to HRv4.0 on 23Aug2022 after OPTIMUM results showed a significant benefit in HR patients for use of CD38 monoclonal antibody across the whole treatment pathway (induction, consolidation and maintenance). Patients registered after this point were not randomised but instead received Isa-VRDc induction, Isa-VRD consolidation and Isa-R maintenance. No formal statistical analysis can be performed due to the premature closure of R3. Here we described the results of HR patients registered prior to the amendment who were randomised.
Results
26 patients were randomised between 11Sept2020 and 20Mar2023. Median age was 58 years, and 92.3% achieved ≥VGPR at the time of randomisation (100 days post-ASCT). R-ISS stage at diagnosis (I/II/III/missing) were 38.5%/53.8%/3.8%/3.8% respectively. All patients had 2 HRCA and 3/26 had ≥3 HRCA.
At a median follow-up of 40 (IQR: 38,43) months, all patients received treatment and treatment modifications were comparable across the two arms. PFS at 28 months was 53.8% (95%CI: 25.1,80.8) in the IsaVRD/IsaR arm and 38.5% (95%CI: 13.9,68.4) in VRD/R arm. Median PFS was 33 (95%CI: 13, NR) months in IsaVRD/IsaR arm and 17 (95%CI: 8, NR) months in VRD/R arm. Median time to next treatment from trial registration was 42 months (95%CI: 17, NR) for IsaVRD/IsaR and 22 months (95%CI: 17, NR) for VRD/R arm. ≥VGPR rates were comparable across both arms at 3, 6 and 12 months post ASCT. MRD negativity at 100 days and 12 months post-ASCT were 23.1% and 44.4% in the IsaVRD/IsaR arm and 30.8% and 22.2% in the VRD/R arm.
19 SAEs were reported from 12 patients, with 15/19 SAE’s in IsaVRD/IsaR arm. Majority of the SAE’s reported (13/19) were infections and infestations. There were no treatment related deaths.
Conclusions
RADAR demonstrates the feasibility to seamlessly amend a Phase II/III trial in an evolving therapeutic landscape, whilst still obtaining important descriptive results. The addition of Isa to consolidation and maintenance IsaVRD/IsaR appears to improve time to next treatment and PFS in double hit myeloma patients. This may be driven by the higher MRD negativity rates. Ongoing immune correlative studies will dissect the mechanisms underlying the deepening of responses achieved by the use of CD38 blockade to post-ASCT therapy in this and other RADAR pathways.
DISCLOSURES
Karthik Ramasamy, MD PhD: Sanofi - Honoraria; Johnson and Johnson - Honoraria; BMS ( Celgene) - Honoraria; GSK - Honoraria; Menarini stemline - Honoraria; Recordati - Honoraria; Adaptive biotech - Honoraria; Sebia - Honoraria; amgen - Honoraria; Takeda - Honoraria; Pfizer - Honoraria; Astra zeneca - Honoraria; GSK - Research Funding; Johnson and Johnson - Research Funding; amgen - Research Funding; Pfizer - Research Funding; BMS ( Celgene) - Research Funding; Thermofisher ( TBS) - Research Funding; Sanofi - Research Funding; GSK - Consultancy (Includes expert testimony); Adaptive biotech - Consultancy (Includes expert testimony); Thermofisher ( TBS) - Consultancy (Includes expert testimony); Astra zeneca - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); amgen - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Menarini stemline - Consultancy (Includes expert testimony); Recordati - Consultancy (Includes expert testimony); BMS ( Celgene) - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)